Prostate Cell News Volume 12.39 | Oct 15 2021

    By
    Justin.choi
    -
    0
    35






    2021-10-15 | PCN 12.39


    Prostate Cell News by STEMCELL Technologies
    Vol. 12.39 – 15 October, 2021
    TOP STORY

    Supraphysiological Testosterone Induces Ferroptosis and Activates Immune Pathways through Nucleophagy in Prostate Cancer

    Investigators reported that supraphysiological levels of testosterone (SupraT) activated cytoplasmic nucleic acid sensors and induced growth inhibition of SupraT-sensitive prostate cancer cells.
    [Cancer Research]

    Abstract
    Activate, expand, and differentiate your cells with cytokines, chemokines, and growth factors from STEMCELL Technologies.
    PUBLICATIONSRanked by the impact factor of the journal

    Targeting KDM6A Suppresses SREBP1c-Dependent Lipid Metabolism and Prostate Tumorigenesis

    Scientists reported that specific homozygous deletion of KDM6A in the adult mouse prostate epithelium strongly inhibited tumor progression initiated by the homozygous loss of PTEN. Mechanistically, KDM6A promoted prostate tumorigenesis and lipid metabolism by binding to the SREBP1c promoter which resulted in increased SREBP1c transcription.
    [Cancer Research]

    Abstract

    AXL Cooperates with EGFR to Mediate Neutrophil Elastase-Induced Migration of Prostate Cancer Cells

    Researchers reported that neutrophil elastase triggered dose-dependent ERK signaling and cell migration in a panel of prostate cell lines that represented the spectrum of prostate cell malignancy.
    [iScience]

    AbstractGraphical Abstract

    OXER1 Mediates Testosterone-Induced Calcium Responses in Prostate Cancer Cells

    The authors reported that testosterone, independently of the presence of the classical androgen receptor, rapidly increased intracellular calcium from calcium stores, through the oxoeicosanoid receptor 1 (OXER1) and a signaling cascade that triggered calcium release from the endoplasmic reticulum.
    [Molecular and Cellular Endocrinology]

    Abstract

    Mechanisms of Abemaciclib, a CDK4/6 Inhibitor, Induced Apoptotic Cell Death in Prostate Cancer Cells In Vitro

    Investigators analyzed in vitro cytotoxic and apoptotic effects of abemaciclib on metastatic castration-resistant prostate cancer androgen receptor negative PC-3 and AR mutant LNCaP prostate cancer cells.
    [Translational Oncology]

    Full Article

    Novel Chemotherapeutic Agent FX-9 Activates NF-κB Signaling and Induces G1 Phase Arrest by Activating CDKN1A in a Human Prostate Cancer Cell Line

    Scientists conducted microarray gene expression analysis and compared FX-9 exposed and unexposed prostate cancer cells, followed by pathway analysis and gene annotation to functional processes.
    [BMC Cancer]

    Full Article

    Bortezomib Potentiates Antitumor Activity of Mitoxantrone through Dampening Wnt/β-Catenin Signal Pathway in Prostate Cancer Cells

    Researchers determined the anticancer effects of a combination of bortezomib and mitoxantrone by apoptosis and proliferation assay in vivo and in vitro.
    [BMC Cancer]

    Full Article

    Dual Akt and Bcl-2 Inhibition Induces Cell-Type Specific Modulation of Apoptotic and Autophagic Signaling in Castration Resistant Prostate Cancer Cell Lines

    The authors elucidated the modulation patterns between apoptosis and autophagy following dual inhibition by Akt inhibitor erufosine and Bcl-2 inhibitor ABT-737 in castration-resistant prostate cancer cell lines, PC-3 and DU-145.
    [Molecular Biology Reports]

    Abstract

    Reorganization of the 3D Genome Pinpoints Non-coding Drivers of Primary Prostate Tumors

    Scientists investigated the molecular mech­­anisms of long non‑coding RNA small nucleolar RNA host gene 16 in the proliferation and metastasis of prostate cancer cells.
    [Molecular Medicine Reports]

    Abstract
    Five tips for returning to the lab after time off
    REVIEWS

    Current Status of Organoid Culture in Urological Malignancy

    Investigators summarize the development and applications of 3D organoid cultures in urological cancers, mainly focusing on prostate, urinary bladder and kidney cancers, and assess the future prospects of this model.
    [International Journal of Urology]

    Full Article
    INDUSTRY AND POLICY NEWS

    Tricol Biomedical Receives NIH Phase IIB Grant to Continue Development of its Hemostatic Device for the Prostate

    Tricol Biomedical, Inc. has received an $853,585 grant from the National Institute Of Diabetes And Digestive And Kidney Diseases. This Phase IIB grant will support final development of Tricol’s proprietary hemostatic device to address bleeding in prostate-related procedures for treatment of both benign and malignant prostate conditions.
    [Tricol Biomedical, Inc. (GlobeNewswire, Inc.)]

    Press Release
    FEATURED EVENT

    FSSCR French Society for Stem Cell Research

    November 9 – 10, 2021
    Montpellier, France

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Position – Cancer Biology

    Albert Einstein College of Medicine – Bronx, New York, United States

    Assistant Professor – Cancer Research

    University of Manitoba – Winnipeg, Manitoba, Canada

    Postdoctoral Fellow – Tumor Heterogeneity and Development of Resistant Cancer

    City of Hope – Los Angeles, California, United States

    Postdoctoral Researcher – Tumor Metabolism in Prostate Cancer

    University of California San Francisco – San Francisco, California, United States

    Faculty and Leadership Positions – Cancer-Focused Target and Drug Discovery

    The University of New Mexico – Albuquerque, New Mexico, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Prostate Cell News Twitter